Abiopharma

🔍 Hayden Tiffany Renee (Executive)

Company: LGL GROUP INC (LGL)

Report Date: 2026-07-15

Detailed Transactions and Holdings:

• Holds 0 shares of Common Stock (Direct)
  Date: 2026-07-15 | Code: H | shares_owned_after: 10,000.00 | Footnotes: F1
• Sold 10,000 shares of Subscription Rights (right to purchase) at $6.9 per share (Derivative)
  Date: 2026-07-15 | Code: S | Expires: 2026-07-15 | Exercise: 2026-06-08 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: Includes 3,333 shares that are fully vested and unrestricted as of the filing date and 6,667 shares that are restricted and subject to vesting, of which 3,333 shares vest on January 16, 2027 and 3,334 shares vest on January 16, 2028, in each case subject to the terms and conditions of the applicable award agreement.
• F2: On June 5, 2026, holders of the Issuer's common stock, par value $0.01 per share (the "Common Stock"), received one transferable subscription right (the "Rights") for each share of Common Stock held by such holder as of June 4, 2026. When exercisable, one (1) Right will entitle their holder to purchase one (1) share of Common Stock at an exercise price of $6.90 per share.